secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001178913-24-000879
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio FY2023 net loss narrows to $8.9M; cash runway into Q2 2025; five oral peptide programs on track
--------------------------------------------------------------------------------

- Net loss for FY2023 was $8.9M ($0.31/share), down from $13.1M ($0.45/share) in FY2022.
- Cash and cash equivalents $11.0M as of Dec 31, 2023; sufficient to fund operations through Q2 2025.
- R&D expenses decreased to $4.5M from $5.8M; G&A decreased to $4.4M from $7.3M due to cost cuts.
- Key 2024 milestones: Phase 1 PK data for EB612 (H1), pre-IND PK for GLP-2 (H1) and OXM (mid-2024), SABRE update.
- Advancing five oral peptide programs: EB613 (osteoporosis), EB612 (hypoparathyroidism), GLP-2, OXM, stress fractures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/0001178913-24-000879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324000879/zk2431116.htm
  HTML page:      https://secwatch.observer/filing/0001178913-24-000879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer